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Fig 1. Erythematous, tender papules and nodules with
hemorrhagic crusting on the face and lips, consistent with
a clinical diagnosis of Sweet syndrome.
Fig 2. Skin biopsy from the arm with a dense dermal
neutrophilic infiltrate with cellular debris. Hematoxylin-
eosin stain; original magnifications: 32; inset, 320.
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debris but no fibrinoid changes of vasculitis (Fig 2).
Special stains were negative for microorganisms
( fungal, bacterial, acid-fast). The clinical and
histopathologic findings were consistent with a
diagnosis of Sweet syndrome. She was treated with
high-dose intravenous corticosteroids (1.8 mg/kg
prednisone equivalent) and dapsone with dramatic
clinical improvement. A slow taper of corticosteroids
was initiated after 2 weeks of treatment with no
resulting rebound.
This case appears to meet criteria for drug-
induced Sweet syndrome (DISS), given the
abrupt onset of a typical rash, associated fever,
features of neutrophilic dermatosis on histo-
pathology, an appropriate temporal relationship
with the suspected drug, and the dramatic
resolution after systemic corticosteroid therapy.
To our knowledge, ipilimumab-induced Sweet syn-
drome has not been previously reported in
the medical literature.1-3 The development of DISS
in a patient receiving immunostimulatory therapy
is particularly interesting given the relative paucity
Open access under CC BY-NC-ND license.of knowledge regarding the pathophysiologic mech-
anism underlying Sweet syndrome. Historically,
Sweet syndrome has been thought of as a hypersen-
sitivity reaction; however, cytokine dysregulation
has also been implicated.4 Given the relative
novelty of ipilimumab use, it remains to be
seen whether CTLA-4 blockade results in an
increased risk for DISS over other immune stimula-
tory therapies.
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To the Editor:Morphologic mimic of Cryptococcus in
a neutrophilic dermatitis (MMCND) is a recently
described entity that is virtually indistinguishable
from cutaneous cryptococcal infection when routine
histopathology is used.
Case: A 63-year-old man with recurrent
Cryptococcus difficile colitis was treated with oral
vancomycin; 24 hours later, an eruption on his back
with ‘‘burning’’ symptoms developed. This eruption
spread to involve his arms and thighs. The next
day, 2 tense bullae appeared on his abdomen. The
Fig 1. Vancomycin-associated neutrophilic dermatitis histo-
logically mimicking Cryptococcus. Clinical images from our
patient exhibiting a diffuse erythematous plaque on the back.
Fig 2. Vancomycin-associated neutrophilic dermatitis
histologically mimicking Cryptococcus. Histologic images
from our patient’s biopsy. Diffuse dermal inflammation
with neutrophils, neutrophilic nuclear debris, and
basophilic bodies with surrounding clear spaces (arrows).
(Hematoxylin-eosin stain; original magnification: 340.)
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Letters e87patient had hemodialysis-dependent end-stage renal
disease, chronic obstructive pulmonary disease,
and coronary artery disease. He took numerous
medications, with vancomycin being the only
recent addition. His physical examination revealed
edematous, erythematous papules coalescing into a
plaque on his back (Fig 1), similar lesions on his
chest, upper extremities, and thighs with 2 tense
bullae on his abdomen. He was afebrile with a
normal white blood cell count.
Histopathologic evaluation demonstrated baso-
philic bodies with surrounding clear spaces
occupying the upper reticular and papillary dermis
(Fig 2). Dermal edema was also appreciated,
with scattered lymphocytes, histiocytes, and neutro-
phils. Gomori methenamine silver and mucin
stains were unremarkable. Lysozyme, CD15, and
myeloperoxidase stains highlighted numerousneutrophils. A direct immunofluorescence study
was negative.
The patient’s vancomycin was discontinued and
he was begun on oral metronidazole. Application of
topical triamcinolone 0.1% cream ameliorated the
symptoms, with the eruption slowly fading over the
ensuing week.
Comment. Ko et al1 reported three MMCND
patients with acute myeloid leukemia, chronic lym-
phocytic leukemia/small lymphocytic lymphoma,
and questionable systemic lupus erythematosus.
Two had cutaneous biopsies demonstrating leuko-
cytoclastic vasculitis early in their clinical course and
failed to respond to systemic steroid therapy;
eventually both died of their diseases. The authors
concluded that both patients’ biopsies represented
Sweet syndrome or a variant thereof. The third
patient was treated with topical metronidazole and
experienced improvement.
The clinical morphology of these lesions varies.
Most consist of erythematous to dusky red papules/
plaques which may develop hemorrhagic necrosis
and ulceration. They were described as painful and
pruritic.
The most salient histologic feature of MMCND is
the basophilic bodies with surrounding vacuolated
spaces resembling the capsule of cryptococcal
organisms. Tissue stains for fungus, however, are
negative, as are stains for mucopolysaccharides.
Ko et al1 employed transmission electron micro-
scopy on affected tissue, concluding that these
bodies represented degenerating cell nuclei under-
going autolysis and apoptosis. The presence in our
patient of smaller debris more characteristic of the
karyorrhexis associated with neutrophil nuclear
destruction would support this contention.
The association between vancomycin administra-
tion and linear IgA disease has been proposed.2
However, an evaluation of the literature failed to
disclose any described cases of vancomycin associ-
ationwith any of thewell-recognized neutrophil-rich
dermatoses including Sweet syndrome, pyoderma
gangrenosum, Behc¸et syndrome, or periodic fever
syndromes. Moreover, vancomycin administration is
more commonly linked to neutropenia than an
increased presence of neutrophils.3 Given the rarity
of MMCND it would be speculative to hypothesize as
to its etiopathogenesis. As subsequent cases are
reported, hopefully greater insight on the nature of
this condition can be elucidated.
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E-mail: alan.boyd@Vanderbilt.eduFig 1. Vismodegib therapy. Multiple basal cell carcinomas
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and squamous cell carcinomas after treatment and
localized radiotherapy (left zygoma).Compassionate use of vismodegib and
adjuvant radiotherapy in the treatment of
multiple locally advanced and inoperable
basal cell carcinomas and squamous cell
carcinomas of the skin
To the Editor: Vismodegib is a small molecule inhi-
bitor of SMO (smoothened), a transcription gene
present in the hedgehog signalingmolecule pathway
and implicated in the proliferation of basal cell
carcinomas (BCCs).1 In January 2012, vismodegib
was approved by the Food and Drug Administration
for the treatment in adults with metastatic BCCs,
for the treatment of locally advanced BCCs that
recurred following surgery, and in patients who are
not candidates for surgery and/or radiation.
Vismodegib is an ineffective treatment for cutaneous
squamous cell carcinomas (SCCs). The use of vismo-
degib for the treatment of BCCs with concurrent
adjuvant radiotherapy for the treatment of SCCs has
not been previously reported in the literature. We
report a case of numerous BCCs and progressive
SCCs, successfully treated with vismodegib and
concurrent external beam radiation, respectively.
An 81-year-old Caucasian man presented with
multiple ulcerative and exophytic lesions on his face,
trunk, and extremities that were concerning for
locally invasive nonmelanoma skin cancers. The
patient had similarly concerning but less extensive
lesions 2 years earlier but declined treatment and
was subsequently lost to follow-up. In the interim,
because of progressive dementia, the Department of
Social Services assigned him a guardian.On exam, the patient had evidence of numerous
extensive tumors of the face, trunk, and extremities
(Fig 1). Consults with dermatologic surgery and
plastic surgery specialists deemed that it was not
feasible to remove all the lesions or treat them with
radiation given their extensive number and severity.
Palliation andhospicewere recommended. In follow-
up, progressive ectropion of the bilateral eyelids with
resultant exposure keratopathy developed, and the
ulcerative lesions on the face, trunk, and extremities
worsened (Fig 1). After discussion with the patient’s
guardian, the patient was started on vismodegib 150
mg daily oral therapy in August 2012. At the patient’s
10-week follow-up, many of the tumors had almost
completely resolved; however, lesions on the left
parietal scalp, left zygoma, and left lower leg showed
evidence of progression. Subsequent biopsies were
consistent with invasive SCCs.
The patient was referred to radiation oncology for
possible radiotherapy. Over the next 7 weeks, the
patient received 60 Gy (intensity modulated radia-
tion therapy technique) and 40/48 Gy (en face
electrons) to the left parietal scalp and left zygoma.
At the patient’s most recent follow-up in August
2013, most of the tumor burden from his BCCs had
